The Alan Turing Institute, the UK’s national institute for data science and artificial intelligence, is launching a strategic research partnership with Roche to tackle critical research in personalised healthcare including better understanding why some patients respond differently to the same treatment. The aim of this five-year partnership is to develop and apply advanced analytics methodologies to generate insights from multiple types of healthcare data. This will improve our understanding of the impact of patients’ individual characteristics on their disease and response to different therapies, with the ultimate goal of enhancing clinical care for people around the world.

Professor Chris Holmes, Programme Director for Health and Medical Sciences at The Alan Turing Institute said, “We are delighted to announce our collaboration with Roche, our first pharmaceutical partner at the Turing. In bringing together our unique perspectives, complementary expertise, and data assets we aim to better understand how and why individuals respond differently to differing treatments. This forms part of the Turing’s wider health initiative, which is dedicated to accelerating the scientific understanding of human disease in order to improve human health across all walks of life.”

James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche, added, “We are deeply invested in further leveraging high quality data, analytics and technologies through our own internal capabilities and external partnerships to better understand the biology of diseases and patients’ outcomes. Our partnership with The Alan Turing Institute will bring together two teams of data scientists to develop advanced analytics methodologies and ultimately enable the generation of novel insights to accelerate and enhance the development of personalised healthcare for patients with unmet needs.”

This expanded research collaboration follows a successful Data Study Group at the Turing in April 2019, and a 12-week research project later the same year, explored in the case study ‘Turing and Roche: Towards tailor-made lung cancer treatment.’